Del Global Technologies of Valhalla, NY, reported strong growthin both revenues and earnings for fiscal 1996, thanks to a combinationof internal revenue growth and the addition of sales from x-rayvendor Gendex, which Del bought earlier this year (SCAN
Del Global Technologies of Valhalla, NY, reported strong growthin both revenues and earnings for fiscal 1996, thanks to a combinationof internal revenue growth and the addition of sales from x-rayvendor Gendex, which Del bought earlier this year (SCAN 12/27/95).
For the year (end-August), Del reported net sales of $43.7million, a company record and a figure that is 35% higher thanthe $32.6 million in revenues reported in fiscal 1995. Net incomewas $2.9 million, compared with $1.9 million in the prior year.
Del's revenues grew at an even greater rate in the fourth quarter,as the Gendex operations began contributing revenue in the middleof Del's third quarter. Del's revenues jumped 45% to $14.4 million,compared with $9.9 million in the fourth quarter of 1995. Netincome for the period was $970,000, compared with $427,000 inthe fourth quarter of 1995.
Medical imaging sales now contribute 59% of Del's revenues,according to chief executive Leonard Trugman. Del saw growth insales of power conversion subsystems for medical imaging applications,and the company's backlog stood at $23 million at year end, Trugmansaid. The company is planning to display a new neonatal imagingsystem at next month's Radiological Society of North America meeting.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.